• UTP Solution: From RNA Synthesis to Assay Design

  2026-08-27

  Discover how UTP Solution supports RNA synthesis, amplification, siRNA workflows, and nucleotide-dependent metabolism. This guide connects reagent selection with assay design inspired by recent findings on TRIM66 and olfactory receptor regulation.

• HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody

  2026-08-26

  This Alexa Fluor 488 secondary reagent connects human antibody profiling with practical immunofluorescence, Western blot, flow cytometry, IHC, and ELISA workflows. Its affinity-purified polyclonal design supports signal amplification while clear species specificity helps researchers avoid common preclinical-to-clinical assay mismatches.

• PP 2 (AG 1879) Experimental Workflows

  2026-08-26

  PP 2 (AG 1879) provides a practical way to dissect Src-family kinase signaling across cancer, immunology, and vascular assays. This guide connects concentration-aware workflows with troubleshooting strategies that distinguish Src-dependent effects from ROS, calcium-channel, cytotoxic, and vehicle-related artifacts.

• ESCO2 in Cancer: Pan-Cancer Evidence and Validation

  2026-08-25

  Huang et al. combine pan-cancer transcriptomic, survival, single-cell, immune-infiltration, and experimental data to examine ESCO2 as a cancer-associated regulator. Their findings link elevated or context-dependent ESCO2 expression with cell-cycle activity, CDK1-associated signaling, and aggressive behavior in selected tumor models, while also defining important limits for biomarker and therapeutic interpretation.

• Phosbind Biotin for Phosphorylation Analysis

  2026-08-25

  Phosbind Biotin enables sequence-independent detection of phosphorylated proteins on PVDF, offering a practical complement to phospho-specific antibodies. This guide translates the OsCPK4–OsCNGC7 rice salt-tolerance study into a time-resolved Western Blot workflow with optimization and troubleshooting guidance.

• SNAI1, EMT, and Stemness in Thymic Tumors

  2026-08-24

  A 2024 study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition and preserves cancer stem cell-like properties in thymic epithelial tumors. Integrated genomic, single-cell, chromatin, interaction, and phosphoproteomic analyses connect SNAI1 to the PIK3R2/p-EphA2 axis and downstream GSK3β/β-catenin signaling, providing a mechanistic framework for studying tumor invasion and microenvironmental remodeling.

• CAMLs in Blood: Phenotypes and Clinical Utility

  2026-08-23

  The reference study positions circulating cancer-associated macrophage-like cells (CAMLs) as phagocytic polyploid giant cancer cells with clinical associations and functional traits relevant to tumor progression. Its prospective, multi-institutional design supports CAMLs as candidate blood-based indicators of disease spread while also highlighting the need to distinguish correlation from direct metastatic causality.

• AZ505: A Practical SMYD2 Inhibitor Workflow

  2026-08-22

  AZ505 combines substrate-competitive SMYD2 inhibition with strong biochemical selectivity, making it useful for connecting methyltransferase activity to cellular phenotypes. This guide translates the compound’s reported renal-fibrosis findings into practical workflows for epigenetic regulation research, cancer biology research, and assay troubleshooting.

• Gepotidacin: From Mechanism to Translation

  2026-08-21

  Gepotidacin (GSK2140944) offers translational researchers a distinctive way to study bacterial topoisomerase biology and fluoroquinolone-resistant pathogens. This thought-leadership article connects structural enzymology, assay design, resistance research, and development strategy while moving beyond the limited scope of a conventional product page.

• Cyclophosphamide: From DNA Damage to Translation

  2026-08-21

  Cyclophosphamide is more than a classic alkylating chemotherapeutic agent: it is a translational tool for connecting hepatic bioactivation, DNA damage, apoptosis, and immune remodeling. This thought-leadership perspective outlines how to design more informative cancer research and conditioning studies while avoiding overinterpretation across models.

• TCEP Hydrochloride for Redox-Aware Assays

  2026-08-20

  Tris(2-carboxyethyl) phosphine hydrochloride supports controlled disulfide reduction, protein analysis, and redox-sensitive sample preparation. This article explains how its chemistry can improve workflow reliability while clarifying what it can—and cannot—contribute to advanced lateral flow assay sensitivity.

• PAD4-IN-2 TFA: Targeted Control of Tumor NETs

  2026-08-20

  PAD4-IN-2 TFA, also known as Compound 5i TFA, links meta-phenylboronic acid tumor targeting with inhibition of the PAD4–H3cit–NET axis. This thought-leadership guide translates the preclinical evidence into practical assay, biomarker, safety, and translational strategies for cancer researchers.

• β-Elemene Workflows for AMPK and Adipogenesis

  2026-08-19

  Build a reproducible 3T3-L1 workflow to test β-Elemene as a regulator of lipid accumulation, insulin resistance, and AMPK signaling. The same compound also supports carefully separated investigations of neuroprotection, inflammation, apoptosis, and analytical standardization.

• Spatial Proteomics Reveals PD-L1–IL-6 Crosstalk in PSC

  2026-08-18

  Orlandi and colleagues use spatial proteomics with cell-cell cross-talk analysis to examine how immune-checkpoint and cytokine signals are organized in human primary sclerosing cholangitis. The study identifies a spatially contextualized relationship between PD-L1 and IL-6 at the epithelial–immune interface, providing a rationale for testing pathway-level interventions while underscoring the limits of inferring causality from tissue associations.

• WP1066: JAK2/STAT3 Insight for Translational Research

  2026-08-18

  WP1066 is a cell-permeable JAK2/STAT3 inhibitor that connects oncology pathway biology with emerging macrophage-focused regeneration research. This article outlines how to use it as a mechanistic probe, interpret context-dependent signaling, and design translational experiments without confusing pathway inhibition with therapeutic activation.

441 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page